This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Tuberculosis (TB)	<i>Mycobacterium tuberculosis</i> secreted antigen 85-C (FbpC; Ag85C)	An <i>in vitro</i> study identified inhibitors of FbpC that could help treat TB. <i>In vitro</i> , optimized compounds bound to FbpC, an enzyme involved in cell wall formation. In cultures of drug-sensitive and drug-resistant <i>M. tuberculosis</i> , the lead compounds inhibited growth compared with no treatment. Next steps include medicinal chemistry optimization of inhibitors and testing in <i>in vivo</i> models of TB. SciBX 3(48); doi:10.1038/scibx.2010.1447 Published online Dec. 16, 2010	Patent application filed; available for nonexclusive, free-of-charge licensing	Scheich, C. <i>et al. J. Med. Chem.</i> ; published online Nov. 12, 2010; doi:10.1021/jm100993z Contact: Markus Schade, Pfizer Inc., Sandwich, U.K. e-mail: markus.schade@pfizer.com